<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><submitter>Lee HK</submitter><funding>NIDDK NIH HHS</funding><pubmed_abstract>Growth hormone (GH) signaling through STAT5B is a central regulator of hepatic metabolism, yet the functional consequences of disease-associated STAT5B variants remain poorly understood. Here, we analyzed mice carrying STAT5B&lt;sup>Y665F&lt;/sup> (gain-of-function) and STAT5B&lt;sup>Y665H&lt;/sup> (loss-of-function) variants and dissect their impact on metabolic regulation. STAT5B&lt;sup>Y665F&lt;/sup> mice developed hepatic lipid accumulation, hypercholesterolemia, and enhanced insulin sensitivity, whereas STAT5B&lt;sup>Y665H&lt;/sup> mice displayed reduced body weight and impaired insulin responsiveness. Transcriptomic analyses revealed that STAT5B&lt;sup>Y665F&lt;/sup> activated lipid, cholesterol, and immune transcriptional programs, while STAT5B&lt;sup>Y665H&lt;/sup> failed to induce these pathways. Notably, STAT5B&lt;sup</pubmed_abstract><journal>bioRxiv : the preprint server for biology</journal><pagination>2025.11.27.691004</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12694592</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Disease-associated mutations in the STAT5B SH2 domain reprogram hepatic cholesterol and lipid metabolism.</pubmed_title><pmcid>PMC12694592</pmcid><funding_grant_id>R01 DK121998</funding_grant_id><pubmed_authors>Hennighausen L</pubmed_authors><pubmed_authors>Waxman DJ</pubmed_authors><pubmed_authors>Pyatkov M</pubmed_authors><pubmed_authors>Liu N</pubmed_authors><pubmed_authors>Ye B</pubmed_authors><pubmed_authors>Demby T</pubmed_authors><pubmed_authors>Lee HK</pubmed_authors><pubmed_authors>Furth PA</pubmed_authors><pubmed_authors>Gavrilova O</pubmed_authors></additional><is_claimable>false</is_claimable><name>Disease-associated mutations in the STAT5B SH2 domain reprogram hepatic cholesterol and lipid metabolism.</name><description>Growth hormone (GH) signaling through STAT5B is a central regulator of hepatic metabolism, yet the functional consequences of disease-associated STAT5B variants remain poorly understood. Here, we analyzed mice carrying STAT5B&lt;sup>Y665F&lt;/sup> (gain-of-function) and STAT5B&lt;sup>Y665H&lt;/sup> (loss-of-function) variants and dissect their impact on metabolic regulation. STAT5B&lt;sup>Y665F&lt;/sup> mice developed hepatic lipid accumulation, hypercholesterolemia, and enhanced insulin sensitivity, whereas STAT5B&lt;sup>Y665H&lt;/sup> mice displayed reduced body weight and impaired insulin responsiveness. Transcriptomic analyses revealed that STAT5B&lt;sup>Y665F&lt;/sup> activated lipid, cholesterol, and immune transcriptional programs, while STAT5B&lt;sup>Y665H&lt;/sup> failed to induce these pathways. Notably, STAT5B&lt;sup</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Dec</publication><modification>2026-06-04T03:20:58.73Z</modification><creation>2026-06-04T03:12:38.467Z</creation></dates><accession>S-EPMC12694592</accession><cross_references><pubmed>41383779</pubmed><doi>10.1101/2025.11.27.691004</doi></cross_references></HashMap>